Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapu003 in advanced mTOR-sensitive solid tumors
NCT07369505Phase 1Recruiting
- Sponsor
- Sapu Nano
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SAP003 in breast cancer, renal cell carcinoma (RCC), Neuroendocrine Neoplasm (NEN) and 2 more, sponsored by Sapu Nano. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose Limiting Toxicities at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
SAP003
03
Conditions
breast cancerrenal cell carcinoma (RCC)Neuroendocrine Neoplasm (NEN)tuberous sclerosis complex (TSC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07369505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369505.